Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bel-sar in Primary Indeterminate Lesions or Small Choroidal Melanoma
NCT06007690Phase 3Active, not recruiting
- Sponsor
- Aura Biosciences, Inc.
- Start
- Dec 2023
- Primary completion
- Nov 2027
- Modality
- Nanoparticles, Recombinant Proteins and Enzymes, Peptide-Drug Conjugates
- Countries
- 14
01
Overview
A Phase 3 trial of belzupacap sarotalocan in choroidal melanoma, sponsored by Aura Biosciences, Inc.. Started Dec 2023; status: active, not recruiting.
02
Drugs
belzupacap sarotalocan
03
Conditions
choroidal melanoma
Beyond the preview
Go deeper on NCT06007690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06007690.